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Airway inflammation is one of the hallmarks of asthma
and can contribute to airway hyperresponsiveness. Using
cynomolgus monkeys (Macaca fascicularis) that are
naturally sensitized to Ascaris suum antigen in the wild,
we developed a reproducible model of acute airway
inflammation following segmental A.suum antigen chal-
lenge. A pediatric bronchoscope was used to perform
bronchoalveolar lavage (BAL) for the collection of BAL
cells and fluid (BALF). The bronchoscope was also used
for the administration of a segmental lung A.suum chal-
lenge. Baseline BAL was performed on one lung prior to
segmental antigen challenge on the opposite lung. BAL
on the challenged lung was performed 24 hours post-
challenge to assess pulmonary inflammation. As com-
pared to baseline lavage, a single airway challenge with
A.suum antigen, at a dose of 0.50 or 0.75 mg/challenge,
resulted in a reproducible pulmonary inflammation. The
inflammation was characterized by an increase in total
BAL cell counts and increased eosinophils. From concen-
trated BALF samples, taken 24 hours post A.suum antigen
challenge, there was also a trend towards increased IL-5
and eotaxin as measured by ELISA. In some studies, ani-
mals were treated with two doses of the steroid, dexa-
methasone (DEX), 1 mg/kg by IM injection, prior to
antigen challenge. In these studies, administration of DEX
prior to antigen challenge prevented airway inflammation.
These data show that segmental challenge with A. suum
antigen produced an acute pulmonary eosinophilic inflam-
mation that was prevented by pretreatment with the ster-
oid, dexamethasone. This model should be useful for
testing the efficacy of selected drug candidates, as com-
pared to proven anti-inflammatory therapy, in blocking
the pulmonary inflammatory response to A. suum in a
large animal model.
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